Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03033680 · ClinicalTrials.gov registry record · Phase 1
Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA
A Phase 1 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT03033680: Completed Phase 1 study, sponsored by Brigham and Women's Hospital.
NCT03033680 is a Phase 1 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 17 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03033680, a Phase 1 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by \[F-18\]PBR06 PET, in subjects with MSA as compared to healthy controls, at baseline and at 9 months follow-up. Secondary: To assess the relationship between microglial activation and clinical progression at baseline and follow-up. Hypothesis: The working hypothesis is that there is microglial activation in Multiple System Atrophy and that the presence and regional distribution of microglial activation is different in MSA versus healthy controls and correlates with disease severity and comorbidities.
Primary Outcome
PET imaging measurement
Interventions
- DRUG [F-18]PBR06
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-03-24 |
| Est. Completion | 2021-01-15 |
| Phase | Phase 1 |
What the finished NCT03033680 record still lists
NCT03033680 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 1 intervention - of which [F-18]PBR06 is the first listed.
NCT03033680 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03033680 about?
NCT03033680 is a clinical study titled "Establishing 18F-PBR06 PET Imaging as a Viable Pharmacodynamic Endpoint in MSA". The specific aims of the study are: Primary: To determine the presence and regional distribution of microglial activation, as assessed by \[F-18\]PBR06 PET, in subjects with MSA as compared to healthy controls, at baseline and at 9 months follow-up. Secondary: To assess the relationship between m...
What is the current status of trial NCT03033680?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2017-03-24. Estimated completion is 2021-01-15.
What interventions are being tested in trial NCT03033680?
The interventions under investigation include: [F-18]PBR06 (DRUG).
Who is sponsoring clinical trial NCT03033680?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03033680's enrollment target sits among peer trials
17 1785th of 2000 higher than 215 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02090140 · 17 participants · NA
Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects
- NCT03317860 · 17 participants · NA
Improving Measurement and Treatment of Post-stroke Neglect
- NCT04356469 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children
- NCT04414046 · 17 participants · Phase 2
TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI